Delivering Revolutionary Cell/Gene Therapies to the Underserved, Creating More Accessibility
By David Jensen,
The California Stem Cell Report
| 04. 24. 2023
What good is a “miraculous” cure or a revolutionary therapy -- which is the goal of a $12 billion state of California enterprise -- if it is not accessible to patients?
That’s a question implicitly posed by a former member of the governing board of that enterprise, the California Institute for Regenerative Medicine (CIRM), more commonly known as the stem cell agency. And he had an answer to the question and a suggestion for the state program.
The remarks come from Jeff Sheehy, who served on the board for 16 years beginning in 2004, the year CIRM was created. He sent the California Stem Cell Report a note after the publication of an article about CIRM’s $80 million effort to create a public-private manufacturing network to overcome obstacles to the production of stem cell and related therapies.
Sheehy spoke to the lack of availability of advanced medical care in underserved areas of California, many of which are rural and remote from the centers where cell and genetic treatments can be done. He proposed that CIRM develop a “capacity...
Related Articles
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...
By Carl Zimmer, The New York Times | 05.31.2024
Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not...
By Liz Szabo, The New York Times | 05.29.2024
By the time Rena Barrow-Wells gave birth to her fourth baby in 2020, she was well-versed in caring for a child with cystic fibrosis. She was also experienced in fighting for a diagnosis of the disease, which runs in families...
By Alison Snyder, Axios | 06.06.2024
Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: ...